Novartis International AG http://www.novartis.com Pharmaceuticals and Alcon performed strongly in the first quarter; overall Group results impacted by expected challenges 2012-04-24T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1605231.shtml Alcon gains exclusive ex-US rights for ocriplasmin, potential first pharmacological treatment for symptomatic vitreomacular adhesion 2012-03-16T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1594547.shtml Novartis delivers strong underlying financial performance in 2011, expects 2012 sales to be in line with 2011 2012-01-25T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2012/1579903.shtml Novartis achieves strong third quarter financial performance and pipeline progress 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1557500.shtml Novartis increases growth potential through integration of Alcon 2011-09-13T12:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1546023.shtml Novartis delivers strong financial results and four major approvals in second quarter of 2011 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1531819.shtml Novartis begins construction of new state-of-the-art pharmaceutical manufacturing plant in St. Petersburg, Russia 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1523978.shtml Alcon wins Patanol® US patent infringement lawsuit against Apotex 2011-05-24T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1518419.shtml Novartis provides restated consolidated income statement data for 2010 and Q1 2011 following the merger with Alcon; no change to total reported Group data 2011-05-18T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1516687.shtml Novartis makes strong start for the year 2011-04-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1507510.shtml Novartis therapy GilenyaTM reduced the risk of MS disability progression regardless of treatment history or disease severity, new analysis shows 2011-04-11T07:05:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1504993.shtml Novartis amends current US FDA application for Afinitor® to seek indication for advanced neuroendocrine tumors of pancreatic origin 2011-04-08T18:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1504913.shtml Novartis completes merger with Alcon 2011-04-08T16:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1504841.shtml Novartis shareholders approve merger of Alcon into Novartis 2011-04-08T11:02:01 CET http://www.novartis.com/newsroom/media-releases/en/2011/1504718.shtml Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis 2011-04-07T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1504246.shtml Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows 2011-03-31T17:30:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1502270.shtml FDA informs Novartis of extension to US regulatory review period for QAB149, a novel once-daily bronchodilator for treatment of COPD 2011-03-23T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1499237.shtml Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China 2011-03-22T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1498805.shtml Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU 2011-03-21T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1498377.shtml Novartis gains positive CHMP opinion for Lucentis® (ranibizumab) to treat vision loss due to macular edema secondary to RVO 2011-03-18T13:18:17 CET http://www.novartis.com/newsroom/media-releases/en/2011/1497952.shtml Novartis committed to provide equivalent of more than USD 3 million in relief aid to Japan earthquake victims 2011-03-17T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1497585.shtml Second Phase III study of Novartis JAK inhibitor INC424 meets primary endpoint in patients with myelofibrosis 2011-03-15T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1496848.shtml FDA advisory committee recommends US approval of Novartis once-daily bronchodilator QAB149 for COPD 2011-03-09T01:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1495541.shtml Novartis to commence subsequent offering period for Genoptix, Inc. 2011-02-28T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1492676.shtml Novartis schedules Extraordinary Shareholder Meeting to vote on Alcon merger for April 8 2011-02-28T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1492572.shtml Shareholders approve all proposed resolutions of Novartis Board of Directors 2011-02-22T17:59:22 CET http://www.novartis.com/newsroom/media-releases/en/2011/1491423.shtml Novartis gains positive CHMP opinion for Rasilamlo(TM), a single-pill combination of aliskiren and amlodipine to treat high blood pressure 2011-02-18T14:04:06 CET http://www.novartis.com/newsroom/media-releases/en/2011/1490537.shtml Novartis appoints Naomi Kelman as new Head of the Novartis OTC division 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1489895.shtml Novartis studies show Onbrez® Breezhaler® plus tiotropium provided greater increase in lung function than tiotropium alone 2011-02-10T09:42:28 CET http://www.novartis.com/newsroom/media-releases/en/2011/1487540.shtml Novartis drug Afinitor® extends progression-free survival in patients with advanced pancreatic NET, study published in NEJM shows 2011-02-09T23:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1487280.shtml FDA approves the Novartis quadrivalent meningococcal conjugate vaccine, Menveo®, for use in children from 2 years of age 2011-01-31T07:15:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1483545.shtml Innovation drives Novartis to double-digit growth for 2010 2011-01-27T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2011/1482782.shtml Novartis to become global leader in eye care, with agreement of 100% merger with Alcon 2010-12-15T06:57:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1472592.shtml Novartis unveils long-term strategy to grow in a dynamically changing healthcare environment 2010-11-17T11:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1463217.shtml Novartis delivers excellent performance in third quarter: recently launched products generate 20%* of sales; Gilenya approved; Alcon consolidated 2010-10-21T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1453762.shtml Swiss law expert counters Alcon Independent Director Committee's legal position in proposed merger with Novartis 2010-09-30T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1447806.shtml Novartis completes 77% majority ownership of Alcon adding new growth platform in eye care to its leading healthcare portfolio 2010-08-26T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1440394.shtml Novartis delivers strong financial performance in second quarter, underpinned by increased momentum in innovation 2010-07-15T07:00:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1431809.shtml Novartis provides progress-update to achieving 77% majority ownership of Alcon 2010-06-30T22:45:00 CET http://www.novartis.com/newsroom/media-releases/en/2010/1428790.shtml Starke Performance der Divisionen Pharmaceuticals und Alcon im ersten Quartal; die Gesamtergebnisse des Konzerns wurden durch erwartete Herausforderungen beeinträchtigt 2012-04-24T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2012/1605233.shtml Novartis plant Bau einer neuen Produktionsanlage für feste Arzneiformen in Stein, Schweiz, für über CHF 500 Millionen 2012-04-23T08:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2012/1604712.shtml Novartis erzielt 2011 eine starke zugrundeliegende finanzielle Performance und erwartet für 2012 einen Umsatz auf dem Niveau des Jahres 2011 2012-01-25T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2012/1579905.shtml Novartis erzielt im dritten Quartal eine starke finanzielle Performance sowie Fortschritte in der Pipeline 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1557502.shtml Novartis erzielt im zweiten Quartal 2011 starke Finanzergebnisse und erreicht vier wichtige Zulassungen 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1531821.shtml Novartis beginnt mit dem Bau einer neuen, hochmodernen pharmazeutischen Produktionsanlage in St. Petersburg, Russland 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1523980.shtml Novartis startet kraftvoll in das Jahr 2011 2011-04-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1507512.shtml Novartis Aktionäre genehmigen Fusion von Alcon und Novartis 2011-04-08T11:02:01 CET http://www.novartis.com/newsroom/media-releases/de/2011/1504720.shtml Novartis verpflichtet sich für die Erdbebenopfer in Japan eine Katastrophenhilfe im Umfang von über USD 3 Mio. bereitzustellen 2011-03-17T07:15:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1497587.shtml Aktionäre folgen sämtlichen Empfehlungen des Verwaltungsrats von Novartis 2011-02-22T17:59:22+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1491437.shtml Novartis ernennt Naomi Kelman zur neuen Leiterin der OTC-Division von Novartis 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/de/2011/1489896.shtml Innovation als treibende Kraft: Novartis erzielt 2010 ein zweistelliges Wachstum 2011-01-27T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2011/1482784.shtml Novartis schliesst Vereinbarung zur 100%igen Fusion mit Alcon ab und übernimmt globale Führungsposition in der Augenheilkunde 2010-12-15T07:38:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1472600.shtml Novartis erzielt im dritten Quartal eine hervorragende Performance: Die jüngsten Produkte steuern 20%* zum Umsatz bei; Gilenya wird zugelassen; Alcon wird konsolidiert 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1453748.shtml Novartis übernimmt die 77%ige Mehrheitsbeteiligung an Alcon und ergänzt ihr führendes Gesundheitsportfolio durch eine neue Wachstumsplattform im Bereich der Augenheilkunde 2010-08-26T11:35:03+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1440553.shtml Gestützt auf eine verstärkte Innovationsdynamik erzielt Novartis im zweiten Quartal eine starke finanzielle Performance 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/de/2010/1431807.shtml Forte performance de Pharmaceuticals et d'Alcon; résultats du Groupe globalement affectés par les défis attendus 2012-04-24T07:00:00 CET http://www.novartis.com/newsroom/media-releases/fr/2012/1605232.shtml Novartis prévoit de consacrer plus de CHF 500 millions à la construction de nouvelles installations de fabrication de formes galéniques solides à Stein, en Suisse 2012-04-23T08:00:00 CET http://www.novartis.com/newsroom/media-releases/fr/2012/1604714.shtml Novartis a réalisé, en 2011, une excellente performance financière sous-jacente et prévoit pour 2012 des ventes au niveau de 2011 2012-01-25T07:00:00 CET http://www.novartis.com/newsroom/media-releases/fr/2012/1579904.shtml Novartis réalise, au troisième trimestre, une excellente performance financière et d'importants progrès dans son pipeline 2011-10-25T08:30:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1557501.shtml Novartis enregistre, au deuxième trimestre 2011, d'excellents résultats financiers et quatre homologations majeures 2011-07-19T07:00:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1531820.shtml Résultat opérationnel core en progression de 29% (+30% tcc) à USD 4,2 milliards et marge core en augmentation de 0,4 point de pourcentage (+2,6 points de pourcentage tcc) Novartis entreprend la construction d'un nouveau site ultramoderne de fabrication de produits pharmaceutiques à Saint-Pétersbourg, en Russie 2011-06-16T17:30:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1523979.shtml Novartis démarre l'année en force 2011-04-19T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1507511.shtml Les actionnaires de Novartis approuvent la fusion-absorption d'Alcon dans Novartis 2011-04-08T11:02:01 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1504719.shtml Novartis s'engage à apporter l'équivalent de plus de USD 3 millions d'aide aux victimes du tremblement de terre au Japon 2011-03-17T07:15:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1497586.shtml Les actionnaires approuvent l'ensemble des résolutions proposées par le Conseil d'administration de Novartis 2011-02-22T17:59:22+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1491436.shtml Novartis nomme Naomi Kelman directrice de la division Novartis OTC 2011-02-17T07:00:00 CET http://www.novartis.com/newsroom/media-releases/fr/2011/1489897.shtml Novartis: l'innovation entraîne une croissance à deux chiffres en 2010 2011-01-27T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2011/1482783.shtml Novartis consolide sa position de leader mondial de l'ophtalmologie en signant un accord de fusion totale avec Alcon 2010-12-15T07:38:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1472598.shtml Novartis réalise une excellente performance au troisième trimestre: les produits lancés récemment génèrent 20%* du chiffre d'affaires, homologation de Gilenya, consolidation d'Alcon 2010-10-21T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1453758.shtml Novartis acquiert une participation majoritaire de 77 % dans Alcon en ajoutant une nouvelle plateforme de croissance dans l'ophtalmologie à son portefeuille de produits de santé de premier plan 2010-08-26T11:35:03+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1440554.shtml Novartis réalise, au deuxième trimestre, une excellente performance financière, soutenue par l'essor grandissant de l'innovation 2010-07-15T07:00:00+01:00 http://www.novartis.com/newsroom/media-releases/fr/2010/1431808.shtml